香港研究人员认为,针对脂肪细胞蛋白质的新抗体在治疗难以治疗的肝癌方面很有希望。 A new antibody targeting a fat cell protein shows promise in treating a hard-to-treat liver cancer, according to Hong Kong researchers.

香港理工大学的研究人员在Terence Lee教授的领导下研制了单克隆抗体,针对FABP4,一种与新陈代谢性机能失调相关的肝脏疾病(MASLD)相关的脂肪细胞蛋白以及相关的肝癌。 Researchers at The Hong Kong Polytechnic University, led by Prof. Terence Lee, have developed a monoclonal antibody that targets FABP4, a fat cell protein linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and associated liver cancer. FABP4抗体中和了FABP4, 减少了肿瘤的生长,促进了免疫反应,为抗目前免疫疗法的某种形式的肝癌提供了潜在的新治疗。 The antibody neutralizes FABP4, reducing tumor growth and boosting immune response, offering a potential new treatment for a form of liver cancer resistant to current immunotherapies. 调查结果发表在《临床调查期刊》上,得到香港创新与技术基金的支持,专利申请和进一步发展正在进行中。 The findings, published in the Journal of Clinical Investigation, are supported by Hong Kong’s Innovation and Technology Fund, with a patent filed and further development underway.